The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cross-talk between Epidermal Growth Factor Receptor and Hypoxia-inducible Factor-1α Signal Pathways Increases Resistance to Apoptosis by Up-regulating Survivin Gene Expression
Open accessAbstract
Although increasing evidence supports a link between epidermal growth factor receptor (EGFR) signaling and resistance to apoptosis, the mechanism by which the EGFR signaling pathway inhibits apoptosis is not well understood. In this study, we found that epidermal growth factor (EGF) stimulation increased the level of expression of the inhibitor of apoptosis protein survivin in breast cancer cells but not in normal mammary epithelial cells. We further demonstrated that activation of survivin gene expression is mediated by oxygen-independent hypoxia-inducible factor (HIF)-1alpha up-regulation in EGF-treated cancer cells. EGFR signaling activated the phosphoinositide 3-kinase/AKT pathway, subsequently increasing the level of HIF-1alpha under normoxic conditions. HIF-1alpha then activated survivin gene transcription through direct binding to the survivin promoter. Furthermore, we found that overexpression of HIF-1alpha small interfering RNA blocks EGF-induced survivin gene up-regulation and increases apoptosis induced by the chemotherapy drug docetaxel. However, transfection of a plasmid expressing HIF-1alpha gene activates survivin gene expression and reduces the apoptotic response. Our results demonstrate a novel pathway for EGFR signaling-mediated apoptosis resistance in human cancer cells. Although the role of HIF-1alpha in regulating cell survival under hypoxic conditions has been studied extensively, our results show that normoxic breast cancer cells utilize cross-talk between EGFR signals and HIF-1alpha to up-regulate the anti-apoptotic survivin gene, providing a strong rationale for the targeting of HIF-1alpha as a therapeutic approach for both hypoxic and normoxic tumor cells. Understanding key molecular events in EGFR signaling-induced apoptosis resistance should provide new information for the development of novel therapeutic agents targeting EGFR, HIF-1alpha, and/or survivin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
(2000) · PubMed · Cited by 1,445
Deveraux, Q. L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2215 · Cited by 1,388
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,244
Validating survivin as a cancer therapeutic target
Altieri, D. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc968 · Cited by 1,206
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
Structural Basis for the Inhibition of Caspase-3 by XIAP
Riedl, S. J., Renatus, M., Schwarzenbacher, R., Zhou, Q., Sun, C., Fesik, S. W., Liddington, R. C., & Salvesen, G. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00274-4 · Cited by 792
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
田中, 慶. (2000) · Medical Entomology and Zoology · doi:10.11501/3179364 · Cited by 559
(2001) · PubMed · Cited by 557
Structural Basis of Caspase Inhibition by XIAP
Huang, Y., Park, Y. C., Rich, R. L., Segal, D., Myszka, D. G., & Wu, H. (2001) · Cell · doi:10.1016/s0092-8674(01)00273-2 · Cited by 467
An IAP-IAP Complex Inhibits Apoptosis
Dohi, T., Okada, K., Xia, F., Wilford, C. E., Samuel, T., Welsh, K., Marusawa, H., Zou, H., Armstrong, R., Matsuzawa, S.-I., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400236200 · Cited by 398
Phillips, R. J., Mestas, J., Gharaee-Kermani, M., Burdick, M. D., Sica, A., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500963200 · Cited by 323
Yang, L. P. H., Cao, Z., Yan, H. M., & Wood, W. C. (2003) · PubMed · Cited by 318
Self-citationAbd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J. A., Rampaul, R. S., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602184 · Cited by 256
Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis
Gibson, S., Tu, S., Oyer, R., Anderson, S. M., & Johnson, G. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17612 · Cited by 248
Hypoxia, HIF-1, and the Pathophysiologi of Common Human Diseases
Semenza, G. L., Agani, F., Feldser, D., Lyer, N., Kotch, L., Laughner, E., & Yu, 1. (2006) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-46825-5_12 · Cited by 241
Suzuki, A., Ito, T., Kawano, H., Hayashida, M., Hayasaki, Y., Tsutomi, Y., Akahane, K., Nakano, T., Miura, M., & Shiraki, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203429 · Cited by 232
Kothari, S., Cizeau, J., McMillan-Ward, E., Israels, S. J., Bailes, M., Ens, K., Kirshenbaum, L. A., & Gibson, S. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206666 · Cited by 218
Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., Sato, M., & Sato, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0491 · Cited by 195
Navolanic, P., Steelman, L., & McCubrey, J. (2003) · International Journal of Oncology · doi:10.3892/ijo.22.2.237 · Cited by 176
Ling, X., Bernacki, R. J., Brattain, M. G., & Li, F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310947200 · Cited by 175
Peng, X.-H., Cao, Z.-H., Xia, J.-T., Carlson, G. W., Lewis, M. M., Wood, W. C., & Yang, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3196 · Cited by 167
Self-citationReis-Filho, J. S., Milanezi, F., Carvalho, S., Simpson, P. T., Steele, D., Savage, K., Lambros, M. B., Pereira, E. M., Nesland, J. M., Lakhani, S. R., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1341 · Cited by 165
Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Fry, M. (2001) · Breast Cancer Research · doi:10.1186/bcr312 · Cited by 148
Camirand, A., Zakikhani, M., Young, F. B. J., & Pollak, M. (2005) · Breast Cancer Research · doi:10.1186/bcr1028 · Cited by 124
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia
Li, Y., Cao, Z., Li, F., Post, D. E., Meir, E. G. V., Zhong, H., & Wood, W. C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302280 · Cited by 115
Self-citationThe EGF/ErbB Receptor Family and Apoptosis
Danielsen, A. J., & Maihle, N. J. (2002) · Growth Factors · doi:10.1080/08977190290022185 · Cited by 113
Post, D., & Meir, E. G. V. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301605 · Cited by 112
EGF receptor expression, regulation, and function in breast cancer
Chrysogelos, S. A., & Dickson, R. B. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666179 · Cited by 105
Qiu, L., Wang, Q., Di, W. J., Jiang, Q. L., Schefeller, E., Derby, S., Wanebo, H. J., Yan, B., & Wan, Y. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.3.823 · Cited by 46
EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway
Wang, Q., & Greene, M. I. (2005) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.05.002 · Cited by 40
Normanno, N. (2005) · Frontiers in bioscience · doi:10.2741/1725 · Cited by 28
Cited by
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Self-citationMetastasis: recent discoveries and novel treatment strategies
Eccles, S. A., & Welch, D. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 721
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Hypoxia-Modified Cancer Cell Metabolism
Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K., & Forsyth, N. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00004 · Cited by 503
Metadata
- Authors
- Peng, X.-H., Karna, P., Cao, Z., Jiang, B.-H., Zhou, M., & Yang, L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 281
- Issue
- 36
- Pages
- 25903-25914
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2111759875
- Cited by
- 300
- References
- 35
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.